Astellas and Pfizer Report Results of Xtandi (enzalutamide) in P-III PROSPER Study for Non-Metastatic Castration-Resistant Prostate Cancer

 Astellas and Pfizer Report Results of Xtandi (enzalutamide) in P-III PROSPER Study for Non-Metastatic Castration-Resistant Prostate Cancer

Astellas and Pfizer Report Results of Xtandi (enzalutamide) in P-III PROSPER Study for Non-Metastatic Castration-Resistant Prostate Cancer

Shots:

  • The P-III PROSPER study involves assessing of Xtandi (160mg, QD) + ADT vs PBO + ADT in 1400 patients with nmCRPC across the US, EU, SA, Canada, and the Asia-Pacific region
  • The P-III PROSPER study resulted in meeting its 2EPs i.e. improvement in the OS. In 2018, the study met its 1EPs of MFS, which is included in Xtandi’s label in the US, EU, Japan & is currently under review in China
  • Xtandi is an androgen receptor inhibitor, indicated to treat patients with CRPC and mCSPC

Click here ­to­ read full press release/ article | Ref: Pfizer | Image: Equities

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post